JP2005514433A - 眼/耳用医薬組成物の粘性及び他の物理的性質の改質の為の無機質ナノ粒子の使用 - Google Patents
眼/耳用医薬組成物の粘性及び他の物理的性質の改質の為の無機質ナノ粒子の使用 Download PDFInfo
- Publication number
- JP2005514433A JP2005514433A JP2003559428A JP2003559428A JP2005514433A JP 2005514433 A JP2005514433 A JP 2005514433A JP 2003559428 A JP2003559428 A JP 2003559428A JP 2003559428 A JP2003559428 A JP 2003559428A JP 2005514433 A JP2005514433 A JP 2005514433A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- nanoparticles
- ophthalmic
- viscosity
- inorganic nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 53
- 230000000704 physical effect Effects 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 82
- 229910021647 smectite Inorganic materials 0.000 claims abstract description 7
- 239000004927 clay Substances 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 3
- 229910000420 cerium oxide Inorganic materials 0.000 claims description 3
- 230000001050 lubricating effect Effects 0.000 claims description 3
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 3
- BMMGVYCKOGBVEV-UHFFFAOYSA-N oxo(oxoceriooxy)cerium Chemical compound [Ce]=O.O=[Ce]=O BMMGVYCKOGBVEV-UHFFFAOYSA-N 0.000 claims description 3
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 229910021536 Zeolite Inorganic materials 0.000 claims description 2
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 230000009974 thixotropic effect Effects 0.000 claims description 2
- 239000010457 zeolite Substances 0.000 claims description 2
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 claims 1
- 229960001545 hydrotalcite Drugs 0.000 claims 1
- 229910001701 hydrotalcite Inorganic materials 0.000 claims 1
- 239000000607 artificial tear Substances 0.000 abstract description 6
- 229910010272 inorganic material Inorganic materials 0.000 abstract description 2
- 239000011147 inorganic material Substances 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 description 26
- 229940094522 laponite Drugs 0.000 description 14
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000006185 dispersion Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 239000003792 electrolyte Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 6
- 239000003139 biocide Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VTUFDOOSZOYXFC-UHFFFAOYSA-N 2-amino-1-(diaminomethylidene)guanidine Chemical class NNC(=N)NC(N)=N VTUFDOOSZOYXFC-UHFFFAOYSA-N 0.000 description 3
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- -1 magadite Chemical compound 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000006254 rheological additive Substances 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 229920000926 Galactomannan Polymers 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002413 Polyhexanide Polymers 0.000 description 2
- 230000000964 angiostatic effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 229910000271 hectorite Inorganic materials 0.000 description 2
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229910052809 inorganic oxide Inorganic materials 0.000 description 2
- 230000002687 intercalation Effects 0.000 description 2
- 238000009830 intercalation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- FWLKKPKZQYVAFR-LVEZLNDCSA-N (e)-but-2-enedioic acid;1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 FWLKKPKZQYVAFR-LVEZLNDCSA-N 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- JSFATNQSLKRBCI-VAEKSGALSA-N 15-HETE Natural products CCCCC[C@H](O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O JSFATNQSLKRBCI-VAEKSGALSA-N 0.000 description 1
- JSFATNQSLKRBCI-UHFFFAOYSA-N 15-Hydroxyeicosatetraenoic acid Chemical compound CCCCCC(O)C=CC=CCC=CCC=CCCCC(O)=O JSFATNQSLKRBCI-UHFFFAOYSA-N 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000270 aliettite Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 229960001232 anecortave Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000030 antiglaucoma agent Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- VNSBYDPZHCQWNB-UHFFFAOYSA-N calcium;aluminum;dioxido(oxo)silane;sodium;hydrate Chemical compound O.[Na].[Al].[Ca+2].[O-][Si]([O-])=O VNSBYDPZHCQWNB-UHFFFAOYSA-N 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940073602 emadine Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229910052622 kaolinite Inorganic materials 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052901 montmorillonite Inorganic materials 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 230000003427 mucosecretory effect Effects 0.000 description 1
- 239000011234 nano-particulate material Substances 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229910000273 nontronite Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960004114 olopatadine Drugs 0.000 description 1
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003863 physical function Effects 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910000275 saponite Inorganic materials 0.000 description 1
- 229910000276 sauconite Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は眼科および耳科用組成物特に眼または耳組織に局所適用するのに適合した組成物の処方を促進するための無機質ナノ粒子材料の使用に基づいている。合成ナノ粒子の使用が好ましい。ここに記載された無機質ナノ粒子は特に、組成物の流動学的性質の制御が必要である眼科および耳科用医薬品組成物の中に使用するのによく適している。該ナノ粒子はこの目的のためには単独で、又はセルロース化合物類、アクリル系ポリマー類、グアー類(guars)、カラゲナン類(carrageenans)、アルギン酸塩類、キサンタンガム類、およびポリビニルピロリドン重合体類のような周知の流動学的添加剤との組合せで、利用されてもよい、
本発明に利用されたナノ粒子は無機材料である。該粒子はコロイド寸法と、大きな表面積と、高いイオン交換能力とを有している。該粒子は以後、概して、「合成無機質ナノ粒子」と称される。
ラポナイト(R)XLG 0.1 0.1 0.1 0.25 0.25
ポロキサミン(Poloxamine)1304
0.1 0.1 0.1 0.1 0.1
塩化ナトリウム 0.5 - 0.5 0.5 -
塩化カリウム 0.05 - 0.05 0.05 -
HPMC 0.3 - - 0.3 -
ホウ酸ナトリウム 0.35 0.35 0.35 0.35 0.35
精製水 十分量 十分量 十分量 十分量 十分量
pH 7.8 7.8 7.8 7.8 7.8
*粘度mPa*s ニュートン ニュートン ニュートン ニュートン ニュートン
(剪断速度85.61s-1 挙動 挙動 挙動 挙動 挙動
で測定) 7.19±0.10 0.91±0.01 1.09±0.01 9.43±0.01 1.40±0.01
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
*ブルックフィールドDVIII+を使用して、ULAスピンドルをもって、室温23℃で測定された。
成分 9819-35A 9819-35B 9819-35C
ラポナイトXLG(ロット00/211) 0.3 0.3125 0.35
プロピレングリコール 1.2 1.2 1.2
ホウ酸 0.6 0.6 0.6
精製水 十分量 十分量 十分量
pH 7.8 7.8 7.8
成分 9819-69A 9819-695B
ラポナイトXLG(ロット00/211) 0.6 0.4
プロピレングリコール 1.2 1.2
ホウ酸 0.4 0.4
精製水 十分量 十分量
pH 7.8 7.8
Claims (10)
- 眼科または耳科用医薬品組成物の粘性またはその他の物理的性質を改質するための無機質ナノ粒子の使用。
- 眼または耳を潤滑にする方法であって、潤滑有効量の無機質ナノ粒子を含有する眼科用組成物を眼または耳に適用することを含む前記方法。
- 眼科または耳科用医薬品組成物であって、組成物の粘性またはその他の物理的性質を改質するのに十分な量の無機質ナノ粒子を含む前記組成物。
- ナノ粒子が(a)100nm未満の、しかし1nmより大きい粒子寸法と;(b)30〜1000m2/gの範囲の表面積と;(c)6.0〜7.8の範囲のpHにおいて全体として負の表面電荷とを有する、請求項3の組成物。
- 組成物が20s-1〜0.01s-1の剪断速度において0.1mPa*s〜10,000mPa*sの粘度を有する、請求項3の組成物。
- ナノ粒子が合成クレー材料から形成されている、請求項3、4または5の組成物。
- 合成クレー材料がスメクタイトクレーを含む、請求項6の組成物。
- ナノ粒子がゼオライト、ヒドロタルサイト(hydrotalcite)、シリカ、酸化アルミニウム、酸化セリウム、酸化チタンおよび酸化亜鉛からなる群から選ばれる、請求項3、4または5の組成物。
- 組成物が溶液である、請求項3、4または5の組成物。
- 組成物がチキソトロープゲルである、請求項3、4または5の組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34296401P | 2001-12-21 | 2001-12-21 | |
PCT/US2002/041249 WO2003059263A2 (en) | 2001-12-21 | 2002-12-20 | Inorganic nanoparticles to modify the viscosity and physical properties of ophthalmic and otic compositions. |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005514433A true JP2005514433A (ja) | 2005-05-19 |
Family
ID=23344065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003559428A Pending JP2005514433A (ja) | 2001-12-21 | 2002-12-20 | 眼/耳用医薬組成物の粘性及び他の物理的性質の改質の為の無機質ナノ粒子の使用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050002970A1 (ja) |
EP (1) | EP1471925A2 (ja) |
JP (1) | JP2005514433A (ja) |
KR (1) | KR20040073503A (ja) |
AU (1) | AU2002367030B2 (ja) |
BR (1) | BR0215149A (ja) |
CA (1) | CA2467764A1 (ja) |
MX (1) | MXPA04004915A (ja) |
WO (1) | WO2003059263A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005514429A (ja) * | 2001-12-21 | 2005-05-19 | アルコン、インコーポレイテッド | 眼/耳用薬物のキャリヤーとしての合成無機質ナノ粒子の使用 |
JP2016517030A (ja) * | 2013-03-15 | 2016-06-09 | ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッドJohnson & Johnson Vision Care, Inc. | クレイ処理が施されたシリコーン含有コンタクトレンズ |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003059193A2 (en) | 2001-12-21 | 2003-07-24 | Alcon, Inc. | Use of nanoparticles as carriers for biocides in ophthalmic compositions |
US20070026069A1 (en) * | 2003-03-28 | 2007-02-01 | Shastri Venkatram P | Biommetic hierarchies using functionalized nanoparticles as building blocks |
US20040242729A1 (en) * | 2003-05-30 | 2004-12-02 | 3M Innovative Properties Company | Stabilized particle dispersions containing surface-modified inorganic nanoparticles |
FR2867386B1 (fr) * | 2004-03-09 | 2008-01-18 | Armand Neumann | Collyre constitue d'une eau argileuse filtree et purifiee de ses particules utilise, pour le traitement des glaucomes |
DE112006002042A5 (de) * | 2005-05-18 | 2008-04-30 | Mijo Ljubicic | Mikronisierte mineralische Materialien und deren Herstellung |
US10100266B2 (en) | 2006-01-12 | 2018-10-16 | The Board Of Trustees Of The University Of Arkansas | Dielectric nanolubricant compositions |
EP1973998B1 (en) | 2006-01-12 | 2022-06-08 | The Board Of Trustees Of The University Of Arkansas | Nanoparticle compositions and methods for making and using the same |
US7959949B2 (en) | 2006-04-27 | 2011-06-14 | University Of Central Florida Research Foundation, Inc. | Functionalized nanoceria composition for ophthalmic treatment |
US9993803B2 (en) * | 2006-09-05 | 2018-06-12 | Cerion, Llc | Method of preparing cerium dioxide nanoparticles |
US20100021561A1 (en) * | 2006-09-21 | 2010-01-28 | Chowhan Masood A | Self-preserved aqueous pharmaceutical compositions |
US9119391B1 (en) | 2007-07-16 | 2015-09-01 | University Of Central Florida Research Foundation, Inc. | Polymer coated ceria nanoparticles for selective cytoprotection |
BRPI0817176A2 (pt) * | 2007-10-30 | 2015-03-17 | Unilever Nv | "métodos para aumentar a viscosidade de solução tensoativa micelar, para estabelecer ou aumentar o comportamento viscoelástico de solução tensoativa micelar, de controlar viscosidade e viscoelasticidade da solução tensoativa micelar e solução tensoativa" |
EP2288258A4 (en) * | 2008-04-25 | 2012-10-31 | Univ Oklahoma | INHIBITION OF NEOVASCULARIZATION BY CERIUM OXIDE NANOPARTICLES |
US8916199B1 (en) | 2008-04-25 | 2014-12-23 | University of Central Florida Research Foundation, Ind. | Inhibition of angiogenesis associated with ovarian cancer by nanoparticles of cerium oxide |
US9127202B1 (en) | 2008-07-18 | 2015-09-08 | University Of Central Florida Research Foundation, Inc. | Biocompatible nano rare earth oxide upconverters for imaging and therapeutics |
EP2151466A1 (en) * | 2008-08-01 | 2010-02-10 | SiNatur GmbH | Biologically active silicic acid |
CN105671124A (zh) * | 2008-12-31 | 2016-06-15 | 3M创新有限公司 | 大肠菌检测方法以及其中使用的试剂盒 |
US8883519B1 (en) | 2009-03-17 | 2014-11-11 | University Of Central Florida Research Foundation, Inc. | Oxidase activity of polymeric coated cerium oxide nanoparticles |
US9585840B1 (en) | 2009-07-10 | 2017-03-07 | University Of Central Florida Research Foundation, Inc. | Redox active cerium oxide nanoparticles and associated methods |
US8795731B1 (en) | 2009-10-12 | 2014-08-05 | University Of Central Florida Research Foundation, Inc. | Cerium oxide nanoparticle-based device for the detection of reactive oxygen species and monitoring of chronic inflammation |
US8877207B2 (en) | 2010-09-17 | 2014-11-04 | University Of Central Florida Research Foundation, Inc. | Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of Alzheimer's disease and associated methods |
US8951539B1 (en) | 2011-06-07 | 2015-02-10 | University Of Central Florida Research Foundation, Inc. | Methods of promoting angiogenesis using cerium oxide nanoparticles |
US9161950B2 (en) | 2011-09-21 | 2015-10-20 | University Of Central Florida Foundation, Inc. | Neuronal protection by cerium oxide nanoparticles |
CA2869554A1 (en) | 2012-04-04 | 2013-10-10 | Duke University | Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury |
US8476206B1 (en) | 2012-07-02 | 2013-07-02 | Ajay P. Malshe | Nanoparticle macro-compositions |
US8486870B1 (en) | 2012-07-02 | 2013-07-16 | Ajay P. Malshe | Textured surfaces to enhance nano-lubrication |
US9463437B2 (en) | 2013-02-14 | 2016-10-11 | University Of Central Florida Research Foundation, Inc. | Methods for scavenging nitric oxide using cerium oxide nanoparticles |
US20190054185A1 (en) * | 2017-08-18 | 2019-02-21 | King Fahd University Of Petroleum And Minerals | Use of nano-sized clay crystallites to restore adhesion among tumor and aging stem cells |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60174715A (ja) * | 1984-01-25 | 1985-09-09 | ビーチャム・グループ・ピーエルシー | 局所適用用二相医薬組成物 |
JPS62111927A (ja) * | 1985-09-27 | 1987-05-22 | ザ、プロクタ−、エンド、ギヤンブル、カンパニ− | 安定な水性医薬懸濁液 |
JPH01502189A (ja) * | 1986-12-08 | 1989-08-03 | アルセコ・インコーポレイテッド | 保存上安定な局所投与用組成物 |
WO1994001074A1 (en) * | 1992-07-13 | 1994-01-20 | Shiseido Company, Ltd. | Composition for dermatologic preparation |
JPH0710776A (ja) * | 1991-03-27 | 1995-01-13 | Alcon Lab Inc | ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物および薬剤含有の該組成物を目に送達する方法 |
JPH11281937A (ja) * | 1998-03-27 | 1999-10-15 | Menicon Co Ltd | コンタクトレンズ用剤 |
JP2001509780A (ja) * | 1995-12-21 | 2001-07-24 | アルコン ラボラトリーズ,インコーポレイテッド | 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用 |
JP2001240547A (ja) * | 2000-02-29 | 2001-09-04 | Lion Corp | 花粉症抑制剤 |
JP2005514429A (ja) * | 2001-12-21 | 2005-05-19 | アルコン、インコーポレイテッド | 眼/耳用薬物のキャリヤーとしての合成無機質ナノ粒子の使用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3947573A (en) * | 1969-12-01 | 1976-03-30 | Burton, Parsons And Company, Inc. | Opthalmic solution |
US3884826A (en) * | 1973-07-20 | 1975-05-20 | Barnes Hind Pharm Inc | Thixotropic cleaning agent for hard contact lenses |
US3974125A (en) * | 1974-09-27 | 1976-08-10 | Exxon Research And Engineering Company | Higher dialkyl dimethyl ammonium clay gelling agents for unsaturated polyester compositions |
US4127423A (en) * | 1977-09-13 | 1978-11-28 | Burton, Parsons And Company, Inc. | Contact lens cleaning solution |
US4120949A (en) * | 1977-10-05 | 1978-10-17 | Cooper Laboratories, Inc. | Ophthalmic solution |
US4271143A (en) * | 1978-01-25 | 1981-06-02 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
US4394179A (en) * | 1979-06-25 | 1983-07-19 | Polymer Technology Corporation | Abrasive-containing contact lens cleaning materials |
US4374745A (en) * | 1981-08-13 | 1983-02-22 | Barnes-Hind Pharmaceuticals, Inc. | Cleaning compositions |
US4804539A (en) * | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
IL80298A (en) * | 1986-10-14 | 1993-01-31 | Res & Dev Co Ltd | Eye drops |
US4891043A (en) * | 1987-05-28 | 1990-01-02 | Board Of Trustees Of The University Of Illinois | System for selective release of liposome encapsulated material via laser radiation |
US4923699A (en) * | 1988-06-03 | 1990-05-08 | Kaufman Herbert E | Eye treatment suspension |
US5037647A (en) * | 1988-09-15 | 1991-08-06 | Alcon Laboratories, Inc. | Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride |
US5674504A (en) * | 1989-07-12 | 1997-10-07 | L'oreal | Cosmetic composition in the form of an aqueous gel containing in suspension spheroids of a non-hydrophilic, lipoidal substance |
US5185152A (en) * | 1990-01-10 | 1993-02-09 | Peyman Gholam A | Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye |
EP0546728A3 (en) * | 1991-12-13 | 1993-09-08 | Alcon Laboratories Inc | Physiological tear compositions and methods for their preparation |
US5139782A (en) * | 1991-12-23 | 1992-08-18 | Uop | Facial cleansing mineral compositions |
US5394179A (en) * | 1992-03-20 | 1995-02-28 | Scitex Digital Printing, Inc. | Stimulator for continous ink print head |
US5505953A (en) * | 1992-05-06 | 1996-04-09 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
US5532224A (en) * | 1993-12-22 | 1996-07-02 | Alcon Laboratories, Inc. | Contact lens cleaning composition containing polyalklene oxide modified siloxanes |
WO1996003158A1 (en) * | 1994-07-22 | 1996-02-08 | Alcon Laboratories, Inc. | Use of low molecular weight amino acids in ophthalmic compositions |
US5585108A (en) * | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US6015816A (en) * | 1996-02-29 | 2000-01-18 | The Research Foundation Of State University Of New York | Antimicrobial compositions |
KR20000036193A (ko) * | 1996-09-20 | 2000-06-26 | 스티븐 에이. 헬렁 | 콘택트 렌즈를 재습윤시키고 안구 건조감을 경감시키는 방법 및조성물 |
US5811580A (en) * | 1996-12-04 | 1998-09-22 | The Lubrizol Corporation | Process for the preparation of N-hydrocarbyl-substituted amides via the ritter reaction using solid clay catalysts |
KR100366676B1 (ko) * | 1996-12-13 | 2003-01-14 | 알콘 래보레이토리스, 인코퍼레이티드 | 안과용 조성물에 저분자량 아미노 알코올을 사용하는 방법 |
US5858346A (en) * | 1997-05-09 | 1999-01-12 | Allergan | Compositions and methods for enhancing contact lens wearability |
EP1348427B1 (en) * | 1997-07-29 | 2008-04-09 | Alcon Laboratories, Inc. | Ophthalmic compositions containing galactomannan polymers and borate |
PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
-
2002
- 2002-12-20 EP EP02806508A patent/EP1471925A2/en not_active Withdrawn
- 2002-12-20 AU AU2002367030A patent/AU2002367030B2/en not_active Ceased
- 2002-12-20 WO PCT/US2002/041249 patent/WO2003059263A2/en active Application Filing
- 2002-12-20 JP JP2003559428A patent/JP2005514433A/ja active Pending
- 2002-12-20 CA CA002467764A patent/CA2467764A1/en not_active Abandoned
- 2002-12-20 BR BR0215149-9A patent/BR0215149A/pt not_active IP Right Cessation
- 2002-12-20 MX MXPA04004915A patent/MXPA04004915A/es not_active Application Discontinuation
- 2002-12-20 US US10/494,710 patent/US20050002970A1/en not_active Abandoned
- 2002-12-20 KR KR10-2004-7009785A patent/KR20040073503A/ko not_active Application Discontinuation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60174715A (ja) * | 1984-01-25 | 1985-09-09 | ビーチャム・グループ・ピーエルシー | 局所適用用二相医薬組成物 |
JPS62111927A (ja) * | 1985-09-27 | 1987-05-22 | ザ、プロクタ−、エンド、ギヤンブル、カンパニ− | 安定な水性医薬懸濁液 |
JPH01502189A (ja) * | 1986-12-08 | 1989-08-03 | アルセコ・インコーポレイテッド | 保存上安定な局所投与用組成物 |
JPH0710776A (ja) * | 1991-03-27 | 1995-01-13 | Alcon Lab Inc | ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物および薬剤含有の該組成物を目に送達する方法 |
WO1994001074A1 (en) * | 1992-07-13 | 1994-01-20 | Shiseido Company, Ltd. | Composition for dermatologic preparation |
JP2001509780A (ja) * | 1995-12-21 | 2001-07-24 | アルコン ラボラトリーズ,インコーポレイテッド | 緑内障および眼虚血の治療のための特定のイソキノリンスルホニル化合物の使用 |
JPH11281937A (ja) * | 1998-03-27 | 1999-10-15 | Menicon Co Ltd | コンタクトレンズ用剤 |
JP2001240547A (ja) * | 2000-02-29 | 2001-09-04 | Lion Corp | 花粉症抑制剤 |
JP2005514429A (ja) * | 2001-12-21 | 2005-05-19 | アルコン、インコーポレイテッド | 眼/耳用薬物のキャリヤーとしての合成無機質ナノ粒子の使用 |
Non-Patent Citations (1)
Title |
---|
JPN7009002919, Bauer, K.H. et. al., Lehrbuch der Pharmazeutischen Technologie, 1999, p.229−230 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005514429A (ja) * | 2001-12-21 | 2005-05-19 | アルコン、インコーポレイテッド | 眼/耳用薬物のキャリヤーとしての合成無機質ナノ粒子の使用 |
JP2016517030A (ja) * | 2013-03-15 | 2016-06-09 | ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッドJohnson & Johnson Vision Care, Inc. | クレイ処理が施されたシリコーン含有コンタクトレンズ |
Also Published As
Publication number | Publication date |
---|---|
WO2003059263A2 (en) | 2003-07-24 |
AU2002367030A1 (en) | 2003-07-30 |
EP1471925A2 (en) | 2004-11-03 |
WO2003059263A3 (en) | 2003-12-04 |
US20050002970A1 (en) | 2005-01-06 |
AU2002367030B2 (en) | 2008-10-16 |
MXPA04004915A (es) | 2004-08-11 |
BR0215149A (pt) | 2004-10-19 |
KR20040073503A (ko) | 2004-08-19 |
CA2467764A1 (en) | 2003-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002367030B2 (en) | Inorganic nanoparticles to modify the viscosity and physical properties of ophthalmic and otic compositions | |
KR100990810B1 (ko) | 안과용 약물 및 이과용 약물을 위한 담체로서 합성 무기 나노입자의 용도 | |
JP6567648B2 (ja) | 薬物のバイオアベイラビリティーの増加および/または眼作用の持続方法 | |
EP3302426A1 (en) | D2o stabilized pharmaceutical formulations | |
EP2437743A1 (en) | Ophthalmic formulations of fluticasone and methods of use | |
JP2010083901A (ja) | キノロンカルボン酸組成物と関連する治療方法 | |
TW201023912A (en) | Pharmaceutical suspension | |
JP2006528990A (ja) | 3種のポリマーの相乗作用的組み合わせを含む眼科用組成物 | |
JP2536806B2 (ja) | ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物 | |
JP2001501194A (ja) | ゲル形成性医薬組成物 | |
MX2012004225A (es) | Formulacion oftalmica y metodo de fabricacion de la misma. | |
US20220241296A1 (en) | Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions | |
JP2003128588A (ja) | 多糖類含有組成物およびその用途 | |
WO2010119942A1 (ja) | レボカバスチン懸濁型点眼剤 | |
EP2827838B1 (en) | Ophthalmic pharmaceutical composition containing a carbonic anhydrase inhibitor and method for the preparation thereof | |
Tripathi et al. | Development of brimonidine niosomes laden contact lenses for extended release and promising delivery system in glaucoma treatment | |
CN118076340A (en) | Ophthalmic pharmaceutical composition and use thereof | |
NZ210871A (en) | Oily, non-aqueous suspension formulation of disodium cromoglycate | |
TW201100071A (en) | Ophthalmic composition and vitamin A stabilization method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051005 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090616 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090916 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090928 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091016 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20091019 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100316 |